Prostate cancer is the leading incident cancer and the second leading cause of cancer deaths among men in the three major U.S. ethnic groups. However, those rates differ markedly among these groups. The racial differences in prostate cancer incidence and mortality could provide important clues to the etiology of the disease that could be exploited to further our understanding of prostate carcinogenesis. Prostate cancer is a model site for the study of the interplay of gene-environment interactions. In this proposed study, we will examine environmental factors in concert with genetic susceptibility in two ethnic groups with contrasting prostate cancer rates, African Americans and Mexican Americans, from a well-defined geographic area. We propose a population-based case-control study of genotypic, phenotypic, environmental and sociodemographic contributors to the etiology of prostate cancer in African Americans and Mexican Americans who are residents of the Houston area (Harris County, Texas). We will enroll 550 prostate cancer cases (200 Mexican Americans and 350 African Americans) and 750 controls (400 Mexican Americans and 350 African Americans) matched on age and race/ethnicity. Constitutional markers of genetic susceptibility and hormonal modulation, such as androgen receptor, 5-alpha-reductase type II, CYP17, CYP1B1, 3-beta-hydroxsteroid type II and vitamin D receptor, will be analyzed to determine if genotypic differences are associated with prostate cancer risk. Few studies have focused on minority populations, especially Hispanics, from a defined geographic area. Understanding how genetic predisposition and exogenous exposures interact to determine prostate cancer susceptibility will allow the development of more effective ethnic-specific prevention strategies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA084964-05
Application #
6645393
Study Section
Special Emphasis Panel (ZRG1-EDC-2 (01))
Program Officer
Arena, Jose Fernando
Project Start
1999-09-30
Project End
2006-07-31
Budget Start
2003-08-01
Budget End
2006-07-31
Support Year
5
Fiscal Year
2003
Total Cost
$433,530
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
Organized Research Units
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Efstathiou, Eleni; Karlou, Maria; Wen, Sijin et al. (2013) Integrated Hedgehog signaling is induced following castration in human and murine prostate cancers. Prostate 73:153-61
Hosain, G M Monawar; Sanderson, Maureen; Du, Xianglin L et al. (2012) Racial/ethnic differences in treatment discussed, preferred, and received for prostate cancer in a tri-ethnic population. Am J Mens Health 6:249-57
Hosain, G M Monawar; Sanderson, Maureen; Du, Xianglin L et al. (2011) Racial/ethnic differences in predictors of PSA screening in a tri-ethnic population. Cent Eur J Public Health 19:30-4
Strom, Sara S; Yamamura, Yuko; Forman, Michele R et al. (2008) Saturated fat intake predicts biochemical failure after prostatectomy. Int J Cancer 122:2581-5
Strom, Sara S; Yamamura, Yuko; Flores-Sandoval, F Nery et al. (2008) Prostate cancer in Mexican-Americans: identification of risk factors. Prostate 68:563-70
Efstathiou, Eleni; Troncoso, Patricia; Wen, Sijin et al. (2007) Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer. Clin Cancer Res 13:1224-31
El-Zein, Randa; Etzel, Carol J; Lopez, Mirtha S et al. (2006) Human sensitivity to PhIP: a novel marker for prostate cancer risk. Mutat Res 601:1-10
Strom, Sara S; Kamat, Ashish M; Gruschkus, Stephen K et al. (2006) Influence of obesity on biochemical and clinical failure after external-beam radiotherapy for localized prostate cancer. Cancer 107:631-9
El-Zein, Randa; Gu, Yun; Sierra, Monica S et al. (2005) Chromosomal instability in peripheral blood lymphocytes and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 14:748-52
Strom, Sara S; Wang, Xuemei; Pettaway, Curtis A et al. (2005) Obesity, weight gain, and risk of biochemical failure among prostate cancer patients following prostatectomy. Clin Cancer Res 11:6889-94

Showing the most recent 10 out of 11 publications